Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (“Bausch Health”), a global, diversified pharmaceutical company, announces the successful completion of its previously announced tender offer to acquire DURECT Corporation (“DURECT”). Under the terms of the agreement, Bausch Health acquired all outstanding shares of DURECT for $1.75 per share in cash, representing a total upfront cash payment of approximately $63 million at closing. The transaction also includes the potential for two additional net sales milestone payments of up to $350 million in the aggregate (subject to certain adjustments in respect of a retention plan) if the milestones are achieved before the earlier of the 10-year anniversary of the first commercial sale in the United States and December 31, 2045.
Read the full article: Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-Stage Liver Disease Portfolio //
Source: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bausch-health-completes-acquisition-of-durect-corporation-expanding-l-1071552